Biotech Firms Confront the Energy Crisis

As California's energy crisis deepens, biotech companies have worries in addition to the ruined experiments and damaged equipment that concern life scientists in academia.1 Soaring energy prices could slowly sap the industry's economic health, and blackouts could spoil large batches of drugs by interrupting FDA-mandated protocols. "Biotechnology companies in California sort of naively thought that they were located in a First World business environment," says Joseph Dougherty, an analyst at Lehm

Written byDouglas Steinberg
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Some California companies have already prepared, to varying degrees, to meet that threat. "Because you have earthquakes here, you have to have backup power systems," notes Sue Markland Day, president of the Bay Area Bioscience Center in San Francisco. Amgen, for instance, has been preparing for potential power outages since the 1994 Northridge earthquake, according to spokesman David Kaye. The company's emergency generators now cover 70 to 80 percent of its power requirements.

"We can't afford to be without power," says Kaye. "We're the sole source for Epogen and Neupogen in the U.S. So if the power suddenly went out and we lost it for a couple of days, that would cause a major problem for our customers and patients." (Epogen is used to treat anemia, while Neupogen combats various cancer complications.) John Sung, senior director of facilities at Gilead Sciences, worries about the vulnerability of the company's San Dimas ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies